Reassessing Biomarkers: Guiding Second-Line Therapy in Upper GI Cancer
Experts discuss how biomarker testing results should be reassessed or expanded upon disease progression and how they guide the selection of second-line therapies or clinical trial enrollment.
Video content above is prompted by the following:
- How should biomarker testing results be reassessed or expanded upon disease progression, and how do they guide the selection of second-line therapies or clinical trial enrollment?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Related Content
